GKOS Glaukos Corporation

NYSE
$237.60

Glaukos Corporation (GKOS) is expected to report earnings on January 27, 2027, after the market close. The consensus earnings estimate is $0.32 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +12.6% since its last earnings release on October 28, 2026.

Glaukos Beat Consensus Estimates, Raises Guidance
Wednesday, October 28, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Jan 27
Wednesday · 4:05 PM ET
Earnings Whisper
-
vs $0.32
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $241.13

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Glaukos Corporation

Glaukos is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.

Sector

Healthcare

Industry

Medical Appliances/Equipment

Held By 3 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.